Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

BACKGROUND: Apalutamide is a potent androgen receptor (AR) antagonist that targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets. Objective: To evaluate the activity and safety of apalutamide in patients with high-risk nonmetast...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur Urol
Main Authors: Smith, Matthew R., Antonarakis, Emmanuel S., Ryan, Charles J., Berry, William R., Shore, Neal D., Liu, Glenn, Alumkal, Joshi J., Higano, Celestia S., Maneval, Edna Chow, Bandekar, Rajesh, de Boer, Carla J., Yu, Margaret K., Rathkopf, Dana E.
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5568792/
https://ncbi.nlm.nih.gov/pubmed/27160947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.04.023
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares